RT Journal Article
SR Electronic
T1 Higher ratio of plasma omega-6/omega-3 fatty acids is associated with greater risk of all-cause, cancer, and cardiovascular mortality: a population-based cohort study in UK Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.16.23284631
DO 10.1101/2023.01.16.23284631
A1 Zhang, Yuchen
A1 Sun, Yitang
A1 Yu, Qi
A1 Song, Suhang
A1 Brenna, J. Thomas
A1 Shen, Ye
A1 Ye, Kaixiong
YR 2024
UL http://medrxiv.org/content/early/2024/01/10/2023.01.16.23284631.abstract
AB Background Circulating omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) have been associated with various chronic diseases and mortality, but results are conflicting. Few studies examined the role of omega-6/omega-3 ratio in mortality.Methods We investigated plasma omega-3 and omega-6 PUFAs and their ratio in relation to all-cause and cause-specific mortality in a large prospective cohort, the UK Biobank. Of 85,425 participants who had complete information on circulating PUFAs, 6,461 died during follow-up, including 2,794 from cancer and 1,668 from cardiovascular disease (CVD). Associations were estimated by multivariable Cox proportional hazards regression with adjustment for relevant risk factors.Results Risk for all three mortality outcomes increased as the ratio of omega-6/omega-3 PUFAs increased (all Ptrend < 0.05). Comparing the highest to the lowest quintiles, individuals had 26% (95% CI, 15-38%) higher total mortality, 14% (95% CI, 0-31%) higher cancer mortality, and 31% (95% CI, 10-55%) higher CVD mortality. Moreover, omega-3 and omega-6 PUFAs in plasma were all inversely associated with all-cause, cancer, and CVD mortality, with omega-3 showing stronger effects.Conclusions Using a population-based cohort in UK Biobank, our study revealed a strong association between the ratio of circulating omega-6/omega-3 PUFAs and the risk of all-cause, cancer, and CVD mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was supported by the National Institute of General Medical Sciences of the National Institute of Health under the award number R35GM143060 (KY). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UK Biobank received ethical approval from the research ethics committee (reference ID: 11/ NW/0382). Written informed consent was obtained from participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analyzed during the current study are available from the UK Biobank through an application process (www.ukbiobank.ac.uk/).95%CI 95% confidence intervalANOVAAnalysis of varianceBMIBody mass indexCRPC-creative proteinCVDCardiovascular diseaseDHADocosahexaenoic acidDHA%Docosahexaenoic acid to total fatty acids percentage E2 OestradiolEPAEicosapentaenoic acidHRHazard ratioLALinoleic acidLA%Linoleic acid to total fatty acids percentageIGF-1Insulin-like growth factor 1Omega-3%Omega-3 fatty acids to total fatty acids percentageOmega-6%Omega-6 fatty acids to total fatty acids percentagePUFAsPolyunsaturated fatty acidsRefReferenceSDStandard deviationSHBGSex hormone binding globulinTTSTTestosterone